Postoperative management of vulvar cancer
- PMID: 35256421
- DOI: 10.1136/ijgc-2021-002463
Postoperative management of vulvar cancer
Abstract
The primary treatment for resectable vulvar cancer includes wide local excision of the primary tumor and surgical lymph node assessment. Following surgery, up to 40-50% of patients develop a local recurrence. Historically, the strongest predictor of local recurrence is a positive or close margin (defined as <8 mm), although recent studies question the importance of margin status. Post-operative radiotherapy to the vulva is recommended for all women with a positive margin where re-excision is not possible. Radiotherapy may also be considered in the setting of risk factors for local recurrence: close margin, lymphovascular invasion, large tumor size, and/or depth of invasion >5 mm. Nodal assessment is an important component of vulvar cancer management. A negative sentinel node is associated with a low false-negative predictive value (2% in patients with vulvar tumor <4 cm in GOG 173), 2-year groin recurrence rate of 2.3%, and 3-year disease-specific survival rate of 97% in patients with unifocal vulvar tumor <4 cm in the GROningen INternational Study on Sentinel nodes in Vulvar Cancer (GROINSS-V I) study. Thus, patients with tumor size <4 cm (without additional local risk factors) and negative sentinel node can be observed. Patients with sentinel node metastasis ≤2 mm can be treated with post-operative radiotherapy (2-year isolated groin recurrence rate of 1.6% in GROINSS-V II), as a safe alternative to lymphadenectomy. Patients with sentinel node metastasis >2 mm following sentinel node biopsy should undergo inguinofemoral lymphadenectomy followed by post-operative radiotherapy-based on the GROINSS-V II study, the 2-year isolated groin recurrence rate remains unacceptably high (22%) with radiotherapy alone. Retrospective studies suggest that the addition of concurrent chemotherapy to radiotherapy may improve survival. The ongoing GROINSS-V III study is investigating concurrent chemotherapy and radiotherapy dose escalation. The main goal of these post-operative treatments is to reduce the risk of local, and especially groin, recurrences, which are almost universally fatal.
Keywords: radiation; vulvar neoplasms.
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: GROningen INternational Study on Sentinel nodes in Vulvar cancer III (GROINSS-V III/NRG-GY024).Int J Gynecol Cancer. 2023 Apr 3;33(4):619-622. doi: 10.1136/ijgc-2022-004122. Int J Gynecol Cancer. 2023. PMID: 36653060 Free PMC article. Clinical Trial.
-
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.J Clin Oncol. 2021 Nov 10;39(32):3623-3632. doi: 10.1200/JCO.21.00006. Epub 2021 Aug 25. J Clin Oncol. 2021. PMID: 34432481 Free PMC article. Clinical Trial.
-
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.Gynecol Oncol. 2022 Oct;167(1):3-10. doi: 10.1016/j.ygyno.2022.07.017. Epub 2022 Sep 7. Gynecol Oncol. 2022. PMID: 36085090
-
Sentinel node biopsy in vulvar cancer: Implications for staging.Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):812-21. doi: 10.1016/j.bpobgyn.2015.03.007. Epub 2015 Mar 28. Best Pract Res Clin Obstet Gynaecol. 2015. PMID: 25962357 Review.
-
Current management of vulvar cancer.Hematol Oncol Clin North Am. 2012 Feb;26(1):45-62. doi: 10.1016/j.hoc.2011.10.006. Hematol Oncol Clin North Am. 2012. PMID: 22244661 Review.
Cited by
-
European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023.Int J Gynecol Cancer. 2023 Jul 3;33(7):1023-1043. doi: 10.1136/ijgc-2023-004486. Int J Gynecol Cancer. 2023. PMID: 37369376 Free PMC article.
-
Multidisciplinary Vulvar Cancer Management: The Dermatologist's Perspective.Life (Basel). 2024 Dec 27;15(1):19. doi: 10.3390/life15010019. Life (Basel). 2024. PMID: 39859956 Free PMC article. Review.
-
Nursing of Vulvar Cancer Radical Operation Combined with Laparoscopic Inguinal Lymph Node Dissection.Emerg Med Int. 2022 Sep 5;2022:8091114. doi: 10.1155/2022/8091114. eCollection 2022. Emerg Med Int. 2022. Retraction in: Emerg Med Int. 2023 Nov 29;2023:9831045. doi: 10.1155/2023/9831045. PMID: 36105671 Free PMC article. Retracted.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical